All Categories
Publish Date
17.04.202511:25:46
Disclosure Type
ÖDA
Year
--
Period
-
Notification Attachments (0)
New Business Relation
Summary Info
Signature of New Distributorship Agreement
[CONSOLIDATION_METHOD_TITLE][CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_NewBusinessRelationAbstract|
New Business Relation
oda_UpdateAnnouncementFlag|
Update Notification Flag
Hayır (No)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
.
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_NatureOfTheOtherPartyWithWhichNewBusinessRelationWillStart|
Nature Of The Other Party With Which New Business Relation Will Start
Tedarikçi (Supplier)
oda_NameSurnameOrCompanyTitleOfCustomerOrSupplier|
Name Surname Or Company Title Of Customer Or Supplier
Unikeris Limited
oda_IfExistsShareOfCustomerOrSupplierInNetSalesOrCostOfGoodsSoldOnLatestDisclosedProfitOrLossAndOtherComprehensiveIncomeStatementOfCompany|
If Exists Share Of Customer Or Supplier In Net Sales Or Cost Of Goods Sold On Latest Disclosed Profit Or Loss And Other Comprehensive Income Statement Of Company
0
oda_IfExistsShareOfCustomerOrSupplierInTradeReceivablesOrDebtsOnLatestDisclosedStatementofFinancialPositionOfCompany|
If Exists Share Of Customer Or Supplier In Trade Receivables Or Debts On Latest Disclosed Statement of Financial Position Of Company
0
oda_ExpectedStartingDateOfNewBusinessRelation|
Expected Starting Date O fNew Business Relation
17/04/2025
oda_IfExistSignificantProvisionsOfTheContractTextBlock|
If Exist Significant Provisions Of The Contract
Summarized below.
oda_ImpactOfNewBusinessRelationOnCompanyActivities|
Impact Of New Business Relation On Company Activities
Positive impact is expected.
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) and Unikeris Limited signed an exclusive distributorship agreement regarding the import and supply of REVCOVI®️; a drug which has elapegademase-lvlr active substance used in the treatment of Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID).

Following effectiveness of the agreement, GEN will manage the relevant processes regulated by the Turkish Health authorities for the subjected drug and will carry out its supply and sale within the scope of the Named Patient Program (NPP).

The subjected agreement signed for a period of 3 years and expected contribution of subjected drug GEN's 2025 sales will be over TL 160.000.000.



We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.

CAN ONUR DEMİRALP
YATIRIMCI İLİŞKİLERİ UZMANI
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş.
17.04.2025 11:24:59
NotificationsFinancial StatementsCorporate Actions
mkk footer logo

Copyright © 2025 KAP

Merkezi Kayıt Istanbul

Central Securities Depository & Trade Repository of Türkiye